Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

MIRMNYSE / NASDAQHealthcareSmall cap

$96.13+$0.62 (+0.6%)

Last close · Data as of Nov 20, 2026

Market cap
$5.6B
P/E
-241.4x
EV / EBITDA
329.1x
Revenue
$521.3M
Net margin
-4.5%
ROCE
-3.5%

+39.0% over the last year

Mirum Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.0%
3M
-1.0%
6M
-0.8%
1Y
+39.0%
5Y
+512.7%

52-week range

Day change +$0.62 (+0.6%) from $96 to $96 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MIRM, bought on each weekday since 2021.

News & filings

What Mirum Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 23.4 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 54.7% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Read moreShow less

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Sector
Healthcare
Shares outstanding
51.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$5.6B
P/E
-241.4x
P/B
17.9x
EV / EBITDA
329.1x
EV / Sales
10.9x
P/S
10.8x
52-week high
$128.57
52-week low
$64.10

Profitability

Operating margin
-4.2%
Net margin
-4.5%
EBITDA margin
3.3%
ROE
-7.4%
ROCE
-3.5%
ROIC
-1.6%
ROA
-2.8%
Asset turnover
0.62

Growth

Revenue
$521.3M
Revenue growth, 1Y
54.7%
Revenue CAGR, 3Y
89.1%
Net profit growth, 1Y
-73.4%
Free cash flow
$54.9M

Solvency

Current ratio
2.67
Debt / Equity
1.02
Debt / Assets
0.38
CFO / Net profit
-2.39
Cash / Market cap
5.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$521.3M
Cost of revenue$100.2M
Gross profit$421.1M
Operating expenses$443.2M
Research and development$186.2M
Selling, general and administrative$257.0M
Operating income-$22.1M
Interest and other$710.0k
Pretax income-$21.4M
Tax and other$1.9M
Net income-$23.4M

Revenue and net profit

Revenue grew 54.7% in FY2025; net profit is the dashed line.

Mirum Pharmaceuticals, Inc. revenue and net profit by fiscal year
Mirum Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$77.1M-$135.7M
FY2023$186.4M-$163.4M
FY2024$336.9M-$87.9M
FY2025$521.3M-$23.4M

Cash flows

FY2025: $55.8M from operations, $54.9M free after investment (dashed).

Mirum Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Mirum Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$120.1M-$120.4M
FY2023-$70.9M-$91.1M
FY2024$10.3M-$10.7M
FY2025$55.8M$54.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$521.3M+54.7%1Y
EBITDA
$17.2M
Net profit
-$23.4M
Cash from operations
$55.8M+440.7%1Y
Free cash flow
$54.9M
Revenue CAGR, 3Y
89.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$521.3M$17.2M-$23.4M$54.9M-7.4%+54.7%-73.4%

Monthly returns

Month-by-month returns of MIRM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$842.8M
Liabilities$528.1M
Equity$314.7M
Paid-in capital$981.9M
Retained earnings-$667.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MIRM highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Mirum Pharmaceuticals, Inc. (this company)10.9x

Not shown (no positive earnings and no EV / Sales): Terns Pharmaceuticals, Inc., Cogent Biosciences, Inc., CRISPR Therapeutics AG, Scholar Rock Holding Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Mirum Pharmaceuticals, Inc.MIRMthis company$5.6B-241.4x17.9x-7.4%329.1x
Kymera Therapeutics, Inc.KYMR$6.1B—3.9x-19.7%—
Terns Pharmaceuticals, Inc.TERN$6.1B-63.6x6.1x-9.6%-51.0x
Rhythm Pharmaceuticals, Inc.RYTM$6.0B—22.3x-74.8%—
PACS Group, Inc.PACS$5.9B31.0x6.3x20.2%25.0x
Cogent Biosciences, Inc.COGT$5.6B-17.0x10.2x-60.1%-17.2x
Liquidia CorporationLQDA$5.6B-80.7x124.3x-154.0%-128.8x
CRISPR Therapeutics AGCRSP$5.5B—2.9x-30.3%—
Scholar Rock Holding CorporationSRRK$5.4B—22.1x-154.0%—
Peer median—-40.3x8.3x-45.2%-34.1x

Year-to-date ROI

MIRM since 1 January, against earlier years.

Historical volatility

MIRM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Mirum Pharmaceuticals, Inc. operating margin by fiscal year
Mirum Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-170.3%
FY2023-58.6%
FY2024-26.0%
FY2025-4.2%
LineFY2025
Cost of revenueCost Of Revenue$100.2M
Gross profitGross Profit$421.1M
Operating expensesOperating Expense$443.2M
Research and developmentResearch And Development$186.2M
Selling, general and administrativeSelling General And Administration$257.0M
Total expensesTotal Expenses$543.5M
Pretax incomePretax Income-$21.4M

Learn while you research

Academy chapters picked for Mirum Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing55% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →